Susanne Andersson will take position as CFO at Annexin Pharmaceuticals during April 2023, joining the management team. She has long-standing experience as CFO with investor relations responsibility from a number of international listed companies in various industries, including Sedana Medical, Pricer, ChromoGenics and Nordic Mines. Susanne's most recent position was an interim assignment as CFO consultant on Team Interim.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.312 SEK | +1.30% | +5.05% | +20.00% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+20.00% | 9.79M | |
-1.29% | 103B | |
+8.43% | 101B | |
+4.40% | 23.07B | |
-12.15% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.38% | 16.94B | |
+6.74% | 14.07B | |
+37.53% | 12.35B |
- Stock Market
- Equities
- ANNX Stock
- News Annexin Pharmaceuticals AB
- Annexin Pharmaceuticals AB Appoints Susanne Andersson as CFO